Although sodium–glucose cotransporter-2 (SGLT2) inhibitors were originally developed for glycemic control, they have now emerged as a cornerstone therapy in heart failure (HF), demonstrating efficacy regardless of left ventricular ejection fraction (LVEF) status [13]. This evidence concerns the gene SLC5A2 and heart failure.